Zimigut 400 Tablet contains Rifaximin 400 mg, a broad-spectrum, non-systemic antibiotic primarily used to treat gastrointestinal infections caused by susceptible bacteria. Rifaximin acts by inhibiting bacterial RNA synthesis, thereby exerting a bactericidal effect within the intestinal lumen. It is commonly prescribed for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia coli, as well as for the management of hepatic encephalopathy to reduce the risk of recurrent episodes by decreasing ammonia-producing gut bacteria. Additionally, Zimigut 400 is utilized in the treatment of irritable bowel syndrome with diarrhea (IBS-D) and small intestinal bacterial overgrowth (SIBO). Due to its minimal systemic absorption, Rifaximin offers a favorable safety profile with reduced risk of systemic side effects. The medication should be taken orally as directed by a healthcare professional, typically with or without food. Patients should complete the full prescribed course to prevent bacterial resistance. Use is contraindicated in individuals with known hypersensitivity to Rifaximin or rifamycin derivatives. Caution is advised in patients with severe hepatic impairment. Common adverse effects include nausea, abdominal pain, and headache. Zimigut 400 Tablet should be stored at room temperature, away from moisture and heat.